The short version of peptide hormone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-01 and is reviewed periodically as new material appears.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
=== Dez Watkins === Dez Watkins (Martin Hancock) is a fixer working on behalf of Russian foreign intelligence to protect the interests of Tender. He is first seen approaching Rishi Ramdani and financial journalist Jim Dycker at a bar, warding off an apparent scammer. Rishi and Dycker invite Watkins for drinks and go back to Rishi's apartment to do drugs, where Dycker declares his plan to continue investigating Tender despite being fired by his publication. Watkins supplies them cocaine laced with fentanyl and raises the volume on Rishi's stereo before leaving, inciting a noise complaint that draws police to the apartment right as Dycker overdoses and dies from the poisoned drugs; Rishi is arrested while attempting to flee and is subsequently charged with manslaughter. Watkins later stops Whitney from attempting to disappear amidst escalating public scrutiny of Tender's fraud, having tracked him down to New York after Whitney's burner phone connected to airport WiFi. Watkins and Tender board member Ferdinand Schwarzwald (also a Russian asset) force Whitney to proceed with a takeover bid for Pierpoint, and warn Whitney that escape is not an option, with Watkins confirming that he murdered Dycker.
In 2000, Guinness's 1999 advertisement Surfer was named the best television commercial of all time, in a UK poll conducted by The Sunday Times and Channel 4. This advertisement is inspired by the famous 1980s Guinness TV and cinema ad, Big Wave, centred on a surfer riding a wave while a bikini-clad sunbather takes photographs. The 1980s advertisement not only remained a popular iconic image in its own right; it also entered the Irish cultural memory through inspiring a well-known line in Christy Moore's song "Delirium Tremens" (1985). Surfer was produced by the advertising agency Abbott Mead Vickers BBDO; the advertisement can be downloaded from their website. Guinness won the 2001 Clio Award as the Advertiser of the Year, citing the work of five separate ad agencies around the world. In 2002, Guinness applied the Michael Power formula to Asia with the character Adam King. The campaign featured such tag lines as: "Everyday someone, somewhere achieves something new. Sometimes on a grand, dramatic scale. Sometimes on a more personal scale." As of 2004, Guinness ranked among the top three beer labels in Singapore and Malaysia, with a 20 per cent market share across Southeast Asia. Malaysia was the brand's third-largest market in the region and the sixth largest market worldwide. In 2003, the Guinness TV campaign featuring Tom Crean won the gold Shark Award at the International Advertising Festival of Ireland, while in 2005 their Irish Christmas campaign won a silver Shark.
The Combine are a fictional multidimensional alien empire which serve as the primary antagonistic force in the 2004 video game Half-Life 2 and its subsequent episodes developed and published by Valve Corporation. The Combine consist of organic, synthetic, and heavily mechanized elements. They are encountered throughout Half-Life 2, Half-Life 2: Episode One, and Half-Life 2: Episode Two, as well as Half-Life: Alyx, as hostile non-player characters as the player progresses through the games in an effort to overthrow the Combine occupation of Earth. The Combine are depicted as cruel and totalitarian rulers, suppressing dissent with brutality, using systematic violence to police and gradually assimilate humanity into cybernetic machines, rendering humans infertile, and forcibly performing surgery on captured dissenters to transform them into slaves. Throughout the games, player character Gordon Freeman primarily battles transformed humans as well as synthetic and mechanical enemies that are the product of Combine technology. In addition to their role within the Half-Life series, the Combine have been adapted for machinima productions and other works.
Sources: en.wikipedia.org
After the fall of Tripoli in August 2011, only a few towns in western Libya such as Bani Walid, Sebha, and Sirte remained Gaddafist strongholds. Gaddafi was reportedly planning to catch up with his Sebha commander Ali Kanna's Tuareg forces and seek asylum in Burkina Faso. Instead, Gaddafi retreated to his hometown of Sirte, where he convened a meeting with his son Mutassim and intelligence chief Abdullah Senussi and learned that his youngest son Khamis had been killed by a NATO airstrike on 29 August. In the weeks that followed, Gaddafi continued to broadcast defiant audio messages through Syria-based Arrai TV. On 10 September, General Massoud Abdel Hafiz announced the formation of the Republic of Fezzan in Sebha, where Gaddafi would be president for life. Sebha fell on 22 September. Surrounding himself with bodyguards and a small entourage, including Mutassim, security chief Mansour Dhao, and defense minister Abu-Bakr Yunis Jabr, Gaddafi continually changed residences to escape NATO and NTC shelling, devoting his days to prayer and reading the Qur'an. On 20 October, Gaddafi recorded a farewell audio message for his family, later publicized by Al-Hadath, and then broke out of Sirte's District 2 in a joint civilian-military convoy. According to Dhao, it was a "suicide mission" as Gaddafi wanted to die in the Jarref Valley, close to where he was born. At around 08:30, NATO bombers attacked, destroying at least 14 vehicles and killing at least 53 people.
American molecular biologist at the Cold Spring Harbor Laboratory, who proposed the double helical structure of DNA, with Francis Crick. Nobel Prize in Physiology or Medicine (1962). Member Natl. Acad. Sci. USA
=== Temperature: Gas Mark === Gas Mark is a temperature scale, predominantly found on British ovens, that scales linearly with temperature above 135 °C (Gas Mark 1) and scales with the log of Celsius below 135 °C.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.